FDA Approves Lamotrigine Supplement Application by Taro
The FDA has approved a supplemental application for lamotrigine submitted by Taro.
Company
Pharmaceutical intelligence for Taro with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.